Rubén
Pío Osés
Catedrático de Universidad
Hospital Universitario Central de Asturias
Oviedo, EspañaPublications in collaboration with researchers from Hospital Universitario Central de Asturias (3)
2021
-
SRC family kinase (SFK) inhibitor dasatinib improves the antitumor activity of anti-PD-1 in NSCLC models by inhibiting Treg cell conversion and proliferation
Journal for ImmunoTherapy of Cancer, Vol. 9, Núm. 3
2019
-
YES1 drives lung cancer growth and progression and predicts sensitivity to dasatinib
American Journal of Respiratory and Critical Care Medicine, Vol. 200, Núm. 7, pp. 888-899
2015
-
Complement activation product C4d in oral and oropharyngeal squamous cell carcinoma
Oral Diseases, Vol. 21, Núm. 7, pp. 899-904